Hide table of contents

Calculating and comparing impact

Criticism of cost-effectiveness analysis

Criticism of the RCT-based approach

  • Growth and the case against randomista development
    • An argument that research on and advocacy for economic growth in low- and middle-income countries is more cost-effective than the things funded by proponents of randomized controlled trials development. (60 mins - if you’re short on time, read Sections 1-3)
  • Q&A with Elie Hassenfeld
    • Elie, the CEO and co-founder of GiveWell, discusses his organization’s latest research, his views on economic growth, and what he’s changed his mind on lately. (60 mins.)
Comments
No comments on this post yet.
Be the first to respond.